Investigative Treatments for Metastatic Melanoma
Dr Atkins discusses current unmet needs in the treatment landscape for metastatic melanoma and provides an overview of some of the treatments currently under investigation that show promise.
Second-Line Treatments for Metastatic Melanoma
Insights about second-line treatment options for metastatic melanoma and discusses available data for treatment sequencing.
Managing Immune-Related Adverse Events
Immune-related adverse events are often a sign treatment is working. Dr Atkins discusses potential adverse events and how he counsels patients about them.
Treating Stage IV BRAF-Mutated Melanoma
An expert perspective on how to best treat a patient diagnosed with stage IV BRAF-mutated melanoma.
First-Line and Sequencing Treatment Decisions
Dr Atkins shares his approach to first-line treatment and reviews data regarding treatment sequencing from the DREAMseq Trial.
Treatment Options for Metastatic Melanoma
An overview of treatments for metastatic melanoma, including data updates regarding combination options.
Prognosis and Diagnosis of Advanced Melanoma
Michael B Atkins, MD, shares insights on the prognosis of patient’s diagnosed with advanced melanoma and discusses the value of BRAF mutation testing.
Patient Case: A 62-Year-Old Female with Stage IV BRAF-Mutated Melanoma
Michael B. Atkins, MD, reviews a case involving a female patient who was diagnosed with stage IV BRAF-mutated melanoma, and shares insights on the patient’s prognosis and his approach to diagnosis.
Ideal Treatment for Melanoma in the Adjuvant Setting
Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of Oncology and Medicine, Georgetown University School of Medicine, discusses the ideal therapy for melanoma in the adjuvant setting.